Straits Times Index
3,343.88 -4.99 (-0.15%) Nikkei
38,759.98 -163.02 (-0.42%) Hang Seng
18,467.87 +64.87 (+0.35%) FTSE 100
8,262.75 -12.63 (-0.15%) Bitcoin USD
69,163.01 +800.34 (+1.17%) CMC Crypto 200
1,449.77 -18.17 (-1.24%)
ALK-Abelló A/S (0OIR.L)
| Previous close | 140.20 |
| Open | 141.40 |
| Bid | N/A x N/A |
| Ask | N/A x N/A |
| Day's range | 141.40 - 141.40 |
| 52-week range | 70.40 - 141.40 |
| Volume | |
| Avg. volume | 83,278 |
| Market cap | N/A |
| Beta (5Y monthly) | 0.42 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- GlobeNewswire
ALK launches new growth strategy and 2028 financial ambitions
ALK (ALKB:DC / OMX: ALK B / AKBLF) today announced that the Board of Directors has adopted a new corporate strategy (Allergy+) and 2028 financial ambitions. Allergy+ aims to further strengthen ALK’s leadership in allergy immunotherapy, establishing a leading position in food allergy and anaphylaxis, as well as pursuing new innovations to address adjacent allergic conditions with high unmet needs. The strategy targets average revenue growth of minimum 10% in local currencies (5-year CAGR) until 2
- GlobeNewswire
ALK presents positive phase 3 paediatric trial data offering new hope for children with respiratory allergies
At the Annual Congress of the European Academy of Allergy and Clinical Immunology (EAACI) which took part in Valencia in Spain from 31 May to 3 June 2024, the Danish pharmaceutical company ALK presented new data from two paediatric phase 3 clinical trials evaluating SQ sublingual immunotherapy (SLIT) tablets in house dust mite (HDM) and tree pollen respiratory allergy. ALK contributed with a total of 18 scientific abstracts within the EAACI 2024 scientific programme – this included groundbreakin
- GlobeNewswire
ALK’s European registration application for ITULAZAX® for paediatric indication accepted for review
ALK (ALKB:DC / OMX: ALK B / AKBLF) today announced that the European regulatory filing for ITULAZAX® (tree sublingual allergy immunotherapy (SLIT) tablet) in young children has been accepted for review by the relevant health authorities. The European regulatory review process is anticipated to take up to nine months so that, subject to approval, the first market introductions in Europe could take place from the first half of 2025. The data used in the European filing include results from a succe
